Valion Bio Expands Entolimod Platform for Oncology Growth
SAN ANTONIO, Texas, July 14, 2026 Valion Bio, Inc. has announced major strategic progress across its Entolimod platform, advancing...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN ANTONIO, Texas, July 14, 2026 Valion Bio, Inc. has announced major strategic progress across its Entolimod platform, advancing...
San Antonio, Texas, March 26, 2026 In a strategic move to address critical gaps in radiation emergency therapeutics, Tivic...
